Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: RADIATION: Cisplatin-Docetaxel ± Trastuzumab|OTHER: Cisplatin-Docetaxel ± Trastuzumab|DRUG: Cisplatin-Docetaxel ± Trastuzumab
Sponsor: King Faisal Specialist Hospital & Research Center